December 2013

Aldoxorubicin More Effective Than Doxorubicin in STS

February 24, 2014

Clinical Insights

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared with doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas

ALK-Positive Criteria for Determining Crizotinib Use May Fall Short

February 20, 2014

Clinical Insights

The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.

Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2

February 19, 2014

Clinical Insights

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression- free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups.

Analysis Finds Cancer Care Coordination Increases Patient Satisfaction

February 11, 2014

Clinical Insights

An analysis of cancer care coordination over the last 30 years shows that the process offers many benefits to oncology patients, including fewer hospitalizations and visits to emergency departments and increased patient satisfaction with care.

Standardizing Palliative Care Referrals and Distress Assessment

February 10, 2014

Nurse's Notes

In 2012, the American Society of Clinical Oncology (ASCO) recommended routinely offering palliative care to patients with metastatic cancer and uncontrolled symptoms to improve symptom control and quality of life and reduce caregiver burden.

Evidence-Based Guidelines Needed for Immunotherapy-Related Adverse Events

February 07, 2014

Cover Story

As more immunotherapies move from the bench to the bedside, oncology nurses need to develop a thorough understanding of how these treatments work, as well as how their adverse event profiles differ from those typically seen with traditional cytotoxic regimens

Preventing and Managing Treatment-Related Lymphedema

February 06, 2014

Partner Perspectives

Cancer-related lymphedema can result from the cancer or its treatment. It is an accumulation of protein-rich fluid in an interstitial space which may be the result of surgical resection, lymph node dissection, or radiation therapy

Offering Durable Responses With Less Toxicity in Melanoma

January 30, 2014

Cover Story

The results emerging from the PD-1/PD-L1 trials mark a major step forward, noted Rajni Kannan, MN, RN, ANP, in a recent interview on the implications of this research for multiple cancers, including melanoma

Provenge Treatment Team Supports Patients Every Step of the Way

January 29, 2014

Cover Story

The FDA's approval in 2010 of sipuleucel-T (Provenge) marked a milestone in the treatment of men with advanced prostate cancer and ushered in an exciting new immunotherapeutic treatment approach.

Exploring the Leadership Role of Advanced Practice Provider Manager

January 28, 2014

Partner Perspectives

In 2010, Smilow Cancer Hospital (SCH) at Yale New Haven and Yale Cancer Center (YCC) transitioned from a multisite cancer care delivery system that was both university- and hospitalbased to a new, state-of-the-art, 14-story comprehensive cancer center building.

Helping Patients to Manage Dermatologic Toxicities: An Interview With Kathryn Ciccolini, RN, BSN, OCN

January 24, 2014

Feature Story

Dermatologic adverse events (AEs) associated with anticancer therapies can be complex and are best managed with a proactive and holistic approach-one that takes into account not only the physical demands of the regimen itself, but also the many challenges that patients often face involving treatment adherence, quality of life, and psychosocial concerns.

Immunotherapy Poised to Transform Cancer Treatment

January 23, 2014

Feature Story

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castration-resistant prostate cancer.